Skip to main content

Table 1 Clinical and demographic characteristics of the flurbiprofen and control (tramadol) groups

From: Intravenous flurbiprofen for post-thymectomy pain relief in patients with myasthenia gravis

Characteristic Flurbiprofen Control (tramadol) p value*
n 110 90  
Male/female, n (%) 59 (53.6)/51 (46.4) 43 (47.8)/47 (52.2) 0.504
Age at surgery, years 31.1 ± 11.8 30.3 ± 13.1 0.691
Mean disease duration, years 1.5 ± 0.8 1.8 ± 0.9 0.401
With/without medulla symptoms, n (%) 17 (15.5)/93 (84.5) 15 (16.7)/75 (83.3) 0.816
MGFA stage, n (%)    0.954
I 46 (41.8) 38 (42.2)  
IIa 41 (37.3) 33 (36.7)  
IIb 17 (15.5) 15 (16.7)  
IIIa 6 (5.45) 4 (4.44)  
Time of operation (min) 111.8 ± 25.4 116.4 ± 24.0 0.843
Time of chest drainage (d) 2.7 ± 0.5 2.4 ± 0.8 0.927
Myasthenia crisis 4 (3.6) 3 (3.3) 0.911
MGFA stage at 72 h after operation, n (%)    0.931
I 47 (42.7) 39 (43.3)  
IIa 42 (38.2) 33 (36.7)  
IIb 15 (13.6) 14 (15.6)  
IIIa 6 (5.45) 4 (4.44)  
Adverse reactions    
Nausea and vomiting 14 (12.7) 26 (28.9) 0.021
Headache 5 (4.5) 9 (10.0) 0.162
Facial flushing 3 (2.7) 4 (4.4) 0.526
  1. Values are given as median ± SD or (percentage). MGFA, Myasthenia Gravis Foundation Association.
  2. * p-values were calculated by the χ 2 test.